GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cidara Therapeutics Inc (NAS:CDTX) » Definitions » Gross-Profit-to-Asset %

Cidara Therapeutics (Cidara Therapeutics) Gross-Profit-to-Asset %

: 75.04% (As of Sep. 2023)
View and export this data going back to 2015. Start your Free Trial

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Cidara Therapeutics's annualized Gross Profit for the quarter that ended in Sep. 2023 was $49.32 Mil. Cidara Therapeutics's average Total Assets over the quarter that ended in Sep. 2023 was $65.73 Mil. Therefore, Cidara Therapeutics's annualized Gross-Profit-to-Asset % for the quarter that ended in Sep. 2023 was 75.04%.


Cidara Therapeutics Gross-Profit-to-Asset % Historical Data

The historical data trend for Cidara Therapeutics's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cidara Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Gross-Profit-to-Asset %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 28.25 18.65 73.03 104.60

Cidara Therapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Gross-Profit-to-Asset % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 306.40 71.43 160.77 40.68 75.04

Competitive Comparison

For the Biotechnology subindustry, Cidara Therapeutics's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cidara Therapeutics Gross-Profit-to-Asset % Distribution

For the Biotechnology industry and Healthcare sector, Cidara Therapeutics's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Cidara Therapeutics's Gross-Profit-to-Asset % falls into.



Cidara Therapeutics Gross-Profit-to-Asset % Calculation

Cidara Therapeutics's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2022 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2022 )/( (Total Assets (A: Dec. 2021 )+Total Assets (A: Dec. 2022 ))/ count )
=64.288/( (75.325+47.593)/ 2 )
=64.288/61.459
=104.60 %

Cidara Therapeutics's annualized Gross-Profit-to-Asset % for the quarter that ended in Sep. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Sep. 2023 )/( (Total Assets (Q: Jun. 2023 )+Total Assets (Q: Sep. 2023 ))/ count )
=49.324/( (67.986+63.468)/ 2 )
=49.324/65.727
=75.04 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Sep. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Cidara Therapeutics Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Cidara Therapeutics's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cidara Therapeutics (Cidara Therapeutics) Business Description

Traded in Other Exchanges
Address
6310 Nancy Ridge Drive, Suite 101, San Diego, CA, USA, 92121
Cidara Therapeutics Inc is a biotechnology company. It is focused on the discovery, development, and commercialization of novel anti-infectives for the treatment and prevention of diseases. The company's Rezafungin is a novel molecule in the echinocandin class of antifungals. It is developing rezafungin for the first-line treatment and prevention of serious, invasive fungal infections which are associated with high mortality rates. Its other product candidates include CD377, CD388, RSV AVC, HIV AVC, and SARS-CoV-2 AVC.
Executives
Leslie Tari officer: Chief Scientific Officer C/O CIDARA THERAPEUTICS, INC., 6310 NANCY RIDGE DR SUITE 101, SAN DIEGO CA 92121
Taylor Sandison officer: Chief Medical Officer 6310 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Jeffrey Stein director, officer: President & CEO 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Shane Ward officer: CHIEF LEGAL OFFICER C/O VERSARTIS, INC., 4200 BOHANNON DR., SUITE 250, MENLO PARK CA 94025
Preetam Shah officer: CFO & CBO C/O BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF AMERICAS, 28TH FLR., NEW YORK NY 10019
Paul Daruwala officer: Chief Medical Officer 6310 NANCY RIDGE DR, SAN DIEGO CA 92121
Brady Johnson officer: Dir. of Finance & Controller 6310 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Timothy R Franson director 320 WAKARA WAY, SALT LAKE CITY UT 84108
Carin Canale-theakston director C/O CIDARA THERAPEUTICS, INC., 6310 NANCY RIDGE DR STE 101 CA 92121
Bonnie L Bassler director REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
James E. Levine officer: Chief Financial Officer 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Theodore R Schroeder director 12481 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Chrysa Mineo director 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
David L Gollaher director 6310 NANCY RIDGE DR, SAN DIEGO CA 92121
Daniel D Burgess director C/O HOLLIS-EDEN PHARMACEUTICALS, 4435 EASTGATE MALL STE.400, SAN DIEGO CA 92121